Genmab ADR (NASDAQ:GMAB) currently has a daily average trading volume of 1.48M but it saw 1374871 shares traded in last market. With a market cap of 12.68B USD, the company’s current market price of $19.96 came falling about -1.24 while comparing to the previous closing price of $20.21. In past 52 weeks, the stock remained buoying in the range of price level as high as $31.88 and as low as $18.64. In the recent trading on the day, stock has struck highest price mark of $19.75 while lowest mark touched by it was $20.26.
Taking a look at 20-day trading activity of Genmab ADR (GMAB) gives us an average price of $22.24, while its current price level is -37.39% below from 52-week high level whereas it is 7.11% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $21.23 while that of 200 days or SMA-200 reads an average of $23.93. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.07% during that period while stretching the period over a month that decreases to 2.53%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 37.61 which implies that the stock is in neutral territory.
Leerink Partners upgraded its recommendation for the stock as a “Outperform” from “Market Perform” on February 13, 2025 while assigning a price target of $27.
Over the week, GMAB’s stock price is moving -15.82% down while it is 5.66% when we observe its performance for the past one month. Year-to-date it is -4.36% down and over the past year, the stock is showing a downside performance of -36.99%.
The company is expected to be releasing its next quarterly report on 2025-Feb-11, for which analysts forecasted an EPS of 0.25 while estimate for next year EPS is 1.44. In next quarter, company is expected to be making quarterly sales of $6.32B as analysts are expecting the sales for current fiscal year at $25B and seeing the company making $28.78B in sales next year. Moreover, analysts are in estimates of $5.18B for current-quarter revenue.
Currently, Genmab ADR’s total number of outstanding shares is 635.50M with 0.01% of that held by the insiders while 9.31% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 21.67% and return on equity (ROE) at 23.16%. It has a price to earnings ratio (P/E ratio) of 11.40 while having a 11.13 of forward P/E ratio. Stock’s beta reads 1.06. Stock has a price to book (P/B) ratio of 2.49 while price to sale or P/S ratio amounts to 4.07. Its return on asset (ROA) is 19.54% on average.
